NewsBenzingaStifel Maintains Hold on Target, Raises Price Target to $160 Stifel Maintains Hold on Target, Raises Price Target to $160 Benzinga 2026.11.19 14:35 (GMT+0) Open on Benzinga Other news Stifel Maintains Buy on BellRing Brands, Raises Price Target to $18 Guggenheim Reiterates Buy on TJX Companies, Maintains $152 Price Target Walmart's Weight-Loss Drug Windfall Is Losing Steam $1000 Invested In Charles Schwab 15 Years Ago Would Be Worth This Much Today This Aon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday Halozyme Therapeutics Says Disappointed That Higher Regional Court Overturned The Preliminary Injunction Ordering Merck To Refrain From Distributing And Offering Keytruda In Germany
Halozyme Therapeutics Says Disappointed That Higher Regional Court Overturned The Preliminary Injunction Ordering Merck To Refrain From Distributing And Offering Keytruda In Germany